↓ Skip to main content

Dove Medical Press

Article Metrics

Current treatment options for management of anal intraepithelial neoplasia

Overview of attention for article published in OncoTargets and therapy, June 2013
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (84th percentile)
  • High Attention Score compared to outputs of the same age and source (93rd percentile)

Mentioned by

twitter
4 tweeters
patent
3 patents

Citations

dimensions_citation
39 Dimensions

Readers on

mendeley
44 Mendeley
Title
Current treatment options for management of anal intraepithelial neoplasia
Published in
OncoTargets and therapy, June 2013
DOI 10.2147/ott.s38217
Pubmed ID
Authors

Stephen Weis

Abstract

Anal squamous cell cancer is an uncommon malignancy caused by infection with oncogenic strains of Human papilloma virus. Anal cancer is much more common in immunocompromised persons, including those infected with Human immunodeficiency virus. High-grade anal intraepithelial neoplasia (HGAIN), the precursor of anal cancer, is identified by clinicians providing care for patients with anorectal disease, and is increasingly being identified during screening of immunosuppressed patients for anal dysplasia. The traditional treatment for HGAIN has been excision of macroscopic disease with margins. This approach is effective for patients with small unifocal HGAIN lesions. Patients with extensive multifocal HGAIN frequently have recurrence of HGAIN after excision, and may have postoperative complications of anal stenosis or fecal incontinence. This led to the suggestion by some that treatment for HGAIN should be delayed until patients developed anal cancer. Alternative approaches in identification and treatment have been developed to treat patients with multifocal or extensive HGAIN lesions. High-resolution anoscopy combines magnification with anoscopy and is being used to identify HGAIN and determine treatment margins. HGAIN can then be ablated with a number of modalities, including infrared coagulation, CO2 laser, and electrocautery. These methods for HGAIN ablation can be performed with local anesthesia on outpatients and are relatively well tolerated. High-resolution anoscopy-directed HGAIN ablation is evolving into a standard approach for initial treatment and then subsequent monitoring of a disease which should be expected to be recurrent. Another treatment approach for HGAIN is topical treatment, principally with 5-fluorouracil or imiquimod. Topical therapies have the advantage of being nonsurgical and are well suited for treating widespread multifocal disease. Topical treatments have the disadvantage of requiring extended treatment courses and causing a symptomatic inflammatory response. Successful treatment requires adherence to a regime that is uncomfortable at best and at worst painful. Topical treatments can be successful in motivated adherent patients willing to accept these side effects.

Twitter Demographics

The data shown below were collected from the profiles of 4 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 44 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Spain 1 2%
Unknown 43 98%

Demographic breakdown

Readers by professional status Count As %
Researcher 13 30%
Student > Master 7 16%
Student > Doctoral Student 5 11%
Other 4 9%
Student > Bachelor 2 5%
Other 7 16%
Unknown 6 14%
Readers by discipline Count As %
Medicine and Dentistry 29 66%
Biochemistry, Genetics and Molecular Biology 3 7%
Agricultural and Biological Sciences 2 5%
Psychology 1 2%
Social Sciences 1 2%
Other 1 2%
Unknown 7 16%

Attention Score in Context

This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 February 2020.
All research outputs
#2,640,857
of 16,995,670 outputs
Outputs from OncoTargets and therapy
#64
of 2,442 outputs
Outputs of similar age
#25,283
of 162,496 outputs
Outputs of similar age from OncoTargets and therapy
#4
of 44 outputs
Altmetric has tracked 16,995,670 research outputs across all sources so far. Compared to these this one has done well and is in the 84th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,442 research outputs from this source. They receive a mean Attention Score of 2.2. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 162,496 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 84% of its contemporaries.
We're also able to compare this research output to 44 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 93% of its contemporaries.